Trial Profile
A Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine Once Daily Compared to Atazanavir and Ritonavir Plus Tenofovir/Emtricitabine Once Daily in HIV-1 Infected Antiretroviral Therapy Naive Women
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2023
Price :
$35
*
At a glance
- Drugs Abacavir/dolutegravir/lamivudine (Primary) ; Atazanavir; Emtricitabine/tenofovir disoproxil fumarate; Ritonavir
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms ARIA
- Sponsors ViiV Healthcare
- 16 Sep 2022 Status changed from active, no longer recruiting to completed.
- 22 Jul 2022 Planned End Date changed from 15 Jul 2022 to 31 Aug 2022.
- 27 Jun 2022 Planned End Date changed from 31 May 2022 to 15 Jul 2022.